



Vitekta[®] (elvitegravir) – Product Discontinuation

- The [FDA announced](#) the discontinuation of Gilead's [Vitekta \(elvitegravir\)](#) due to business reasons.
 - The discontinuation is not due to product quality, safety or efficacy concerns.
- Vitekta is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in antiretroviral treatment-experienced adults in combination with an HIV protease inhibitor co-administered with [Norvir[®] \(ritonavir\)](#) and other antiretroviral drugs.
- Other currently available integrase inhibitors indicated for the treatment of HIV-1 infection include [Tivicay[®] \(dolutegravir\)](#) and [Isentress[®] \(raltegravir\)](#).



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News[®] is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.